TB/Flu-06E
Candidate Overview
The vaccine platform is based on the live influenza virus vector that is highly attenuated through alteration in NS1 protein function. This effect is achieved by the replacement of immunosuppressive C-terminal part of NS1 open reading frame with foreign sequences, encoding ESAT-6 antigen of M. tuberculosis. Importantly, viral vector itself acts as an adjuvant, stimulating the innate immune system.
Sponsor / Lead Developer: Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation
Development partner(s): Saint-Petersburg State Research Institute of Phthisiopulmonology, The Ministry of Health of the Russian Federation,
Primary Indication: Immunotherapy / Shortening TB treatment
Other Indication(s): Prevention of TB recurrence
Target Population(s): Adolescents, Adults, People cured of active TB, People with active TB, People with MDR-TB, and People with Mtb infection
Target Route of Administration: Intranasal and Sublingual
Immune tissue localization: Lung, Lymph node, and Spleen
Immunological responses: T-cell
Preclinical Animal Models: Ferret, Guinea pig, and Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ TNF-α IL-17 Mycobacterial growth inhibition |
|
| Preferential immune tissue localization | Lung Lymph node Spleen |
|
| Trained immunity | Yes | |
Related Publications
- Truncated NS1 Influenza A Virus Induces a Robust Antigen-Specific Tissue-Resident T-Cell Response and Promotes Inducible Bronchus-Associated Lymphoid Tissue Formation in Mice. (Vaccines, 2025)
- TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis. (Pharmaceutics, 2024)
- Intranasal Immunization with the Influenza A Virus Encoding Truncated NS1 Protein Protects Mice from Heterologous Challenge by Restraining the Inflammatory Response in the Lungs (Microorganisms, 2021)
- Enhancement of the immunogenicity of influenza A virus by the inhibition of immunosuppressive function of NS1 protein. (Microbiol. Indep. Res. J., 2018)
- Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. (Tuberculosis (Edinb.), 2006)
- Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. (Clin Vaccine Immunol., 2006)